Australia’s trusted immunisation experts
28 June 2024 | NewsCall for participants: new NCIRS study on possible links between genes and adverse events after COVID-19 vaccinationRead the full article
Use of Shingrix versus Zostavax in immunocompetent adults aged ≥50 years
Use of Shingrix in immunocompromised adults aged ≥18 years
Use of Shingrix in immunocompetent adults aged ≥50 years
Immunocompetent older adults compared to placebo
Immunocompetent older adults compared to zoster live vaccine (Zostavax)
Immunocompromised older adults compared to placebo or unvaccinated
Note: These GRADE documents should be read as a supplement to Australian Immunisation Handbook recommendations.
View the zoster disease chapter in the Handbook hereView the ATAGI statement on the clinical use of zoster vaccine in older adults in Australia here